{"id":{"repo_id":"cape-town","oai_identifier":"oai:open.uct.ac.za:11427/10687"},"canonical_url":"https://search.dev.ndltd.org/etd/cape-town/oai:open.uct.ac.za:11427/10687","repository":{"repo_id":"cape-town","name":"University of Cape Town","base_url":"https://open.uct.ac.za/oai/request"},"display":{"title":"The development of penguinpox virus (PEPV) as a vaccine vector : transfer vector construction and rescue of virus growth in rabbit kidney cells (RK-13) by vaccinia virus K1","abstract":"Of the many vaccine trials which have taken place, the most promising results have been obtained from the recent phase 3 clinical trial which tested the ability of a dual protein and Canarypox virus recombinant to protect humans against HIV-1 infections. Because poxviruses are being developed as vaccine vectors against a number of diseases, it is important to continue the search for novel poxvirus vectors, in particular, those that do not cross-neutralize one another. This thesis describes the preliminary work performed on the development of Penguinpox virus (PEPV) as a vaccine vector.","abstract_html":"Of the many vaccine trials which have taken place, the most promising results have been obtained from the recent phase 3 clinical trial which tested the ability of a dual protein and Canarypox virus recombinant to protect humans against HIV-1 infections. Because poxviruses are being developed as vaccine vectors against a number of diseases, it is important to continue the search for novel poxvirus vectors, in particular, those that do not cross-neutralize one another. This thesis describes the preliminary work performed on the development of Penguinpox virus (PEPV) as a vaccine vector.","abstract_has_math":false,"creators":["Hu, Nai-Chung"],"institution":"Division of Virology","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Williamson, Anna-Lise","Douglass, Nicola"],"committee_chairs":[],"committee_members":[],"year":2010,"date_issued":"2010","date_published":"2010","updated_at":"2026-07-22T22:22:39Z","subjects":[],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11427/10687","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Williamson, Anna-Lise","Douglass, Nicola"]},{"key":"dc:creator","label":"Author","values":["Hu, Nai-Chung"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2014-12-31T19:27:03Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2014-12-31T19:27:03Z"]},{"key":"dc:date.issued","label":"Date","values":["2010"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["Division of Virology"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Cape Town"]},{"key":"dc:type","label":"Dc Type","values":["Master Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["Masters"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["MSc"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11427/10687"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Includes bibliographical references (leaves 131-137)."]},{"key":"dc:description.abstract","label":"Abstract","values":["Of the many vaccine trials which have taken place, the most promising results have been obtained from the recent phase 3 clinical trial which tested the ability of a dual protein and Canarypox virus recombinant to protect humans against HIV-1 infections. Because poxviruses are being developed as vaccine vectors against a number of diseases, it is important to continue the search for novel poxvirus vectors, in particular, those that do not cross-neutralize one another. This thesis describes the preliminary work performed on the development of Penguinpox virus (PEPV) as a vaccine vector."]},{"key":"dc:title","label":"Title","values":["The development of penguinpox virus (PEPV) as a vaccine vector : transfer vector construction and rescue of virus growth in rabbit kidney cells (RK-13) by vaccinia virus K1"]}]}],"canonical_facts":{"dc:contributor.advisor":["Williamson, Anna-Lise","Douglass, Nicola"],"dc:creator":["Hu, Nai-Chung"],"dc:date.accessioned":["2014-12-31T19:27:03Z"],"dc:date.available":["2014-12-31T19:27:03Z"],"dc:date.issued":["2010"],"dc:description":["Includes bibliographical references (leaves 131-137)."],"dc:description.abstract":["Of the many vaccine trials which have taken place, the most promising results have been obtained from the recent phase 3 clinical trial which tested the ability of a dual protein and Canarypox virus recombinant to protect humans against HIV-1 infections. Because poxviruses are being developed as vaccine vectors against a number of diseases, it is important to continue the search for novel poxvirus vectors, in particular, those that do not cross-neutralize one another. This thesis describes the preliminary work performed on the development of Penguinpox virus (PEPV) as a vaccine vector."],"dc:identifier.uri":["http://hdl.handle.net/11427/10687"],"dc:language.iso":["eng"],"dc:publisher.department":["Division of Virology"],"dc:publisher.institution":["University of Cape Town"],"dc:title":["The development of penguinpox virus (PEPV) as a vaccine vector : transfer vector construction and rescue of virus growth in rabbit kidney cells (RK-13) by vaccinia virus K1"],"dc:type":["Master Thesis"],"dc:type.qualificationlevel":["Masters"],"dc:type.qualificationname":["MSc"]},"updated_at":"2026-07-22T22:22:39Z"}